Now in its third year, the BIO Convention in China will be held November 11-13, 2013 in Beijing, China. A sister event to the BIO International Convention, BIO China will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities in China, where the Rx market is poised to grow to $315 billion in 2020.
For Western companies and investors looking to capitalize on the explosive Chinese market, the BIO Convention in China is a must-attend event. Here’s why:
- This year, we anticipate 1000+ attendees, 400 companies, 100 exhibitors, and 40 company presentations.
- From 2010 to 2012, the number of Chinese and Western collaborations increased by 133%, with 98 deals at a total value of over $3.4 billion.
- Attendees will have the opportunity to participate in BIO One-on-One Partnering™, an interactive environment to intelligently search, contact, and schedule private meetings with potential partners and investors.
- Attendees come from a diverse range of countries and industries, with Chinese delegations representing about 60% of attendees.
- Biotechnology figures prominently in China’s 12th Five-Year Plan. Largely considered their blueprint for strategic economic growth and investment in the country from 2010 to 2015, the plan highlights seven emerging industries that could transform China’s economy and drive growth. As one of these seven pillars, the biotech industry will receive a large slice of the $1.7 trillion pie the Chinese government has allotted for the plan’s implementation.
- China’s Minister of Health has pledged the country will spend an additional $11.8 billion to advance biotech innovation from 2015 to 2020, as the country looks forward to its 13th Five-Year Plan.
How can your company benefit from the burgeoning number of Chinese and Western collaborations? Our program includes an in-depth look at partnering models between Chinese and Western companies, early stage VC funding in China, and China’s private health care industry. We’ll also have science-focused sessions looking at vaccine development as well as the research and development of orphan drugs to treat rare diseases in China. Registration is available here.